GSK’s market-leading Shingrix vaccine proved effective against shingles more than 10 years post-administration, creating a new hurdle for a number of potential competitors.
Shingrix was 82% effective against shingles after 11 years, according to an extension study in adults 50 years and older. In adults 70 years and older, Shingrix maintained a 73% efficacy rate between six and 11 years post-vaccination, GSK reported on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.